GrayBug Vision Receives $44,500,000 Series B Funding

  • Feed Type
  • Date
    5/2/2016
  • Company Name
    GrayBug Vision
  • Mailing Address
    303 Twin Dolphin Drive Redwood City, CA 94065 USA
  • Company Description
    Graybug Vision is developing products to reduce the frequency of dosing for ocular therapies using its injectable controlled release technologies.
  • Website
    http://www.graybug.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $44,500,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The proceeds will be used to further the development of GB-102, Graybug Vision’s lead drug for wet AMD, through Phase 2 clinical trials and to initiate a clinical program for the company’s proprietary glaucoma compound. GB-102, a dual acting inhibitor of VEGF and PDGF receptors, may be administered twice per year in wet AMD patients.
  • M&A Terms
  • Venture Investor
    Deerfield Capital
  • Venture Investor
    OrbiMed
  • Venture Investor
    Clarus Ventures

Trending on Xconomy